Selective urokinase inhibitors based on substituted aryl guanidines

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 12, 2001, Pages 1975-1977

[No Author Info available]

Author keywords

Cancer treatment; Malignancy; Metastasis; uPA; Urokinase

Indexed keywords

CATHEPSIN; GUANIDINE DERIVATIVE; MATRIX METALLOPROTEINASE; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEINASE; SCLEROPROTEIN; UROKINASE; WX 293T;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CARCINOMA CELL; CELL LINE; CELL SURFACE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; PATENT; PROTEIN DEGRADATION; SOLID TUMOR; TUMOR CELL;

EID: 0035207827     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.12.1975     Document Type: Article

References (9)

1. The urokinase plasminogen activator system as a novel target for tumor therapy
2. The plasminogen activator system: Biology and regulation
3. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (Review)
4. Synthetic urokinase inhibitors as potential anti-invasive drugs
5. Selective inhibition of urokinase by substituted phenylguanidines: Quantitative structure relationship analyses
6. (4-Aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase
7. Crystals of the urokinase type plasminogen activator variant βc-uPA in complex with small molecule inhibitors open the way towards structure-based drug design
8. Synthesis and biological activity of peptidyl aldehyde urokinase inhibitors
9. 3-Amidinophenylalanine-based inhibitors of urokinase